

# ASX Announcement

Medibio Limited – 30 SEPT 2016



## Directors Resignation

Medibio Limited (ASX: MEB) (“Medibio” or the “Company”) announces that Dr James Campbell has resigned as a Non-Executive Director of Medibio Limited, effective close of business today.

Dr Campbell was appointed 8 September 2014 and resigns due to pressure of his other executive and non-executive roles. Medibio thanks him for his valuable contribution to the Board and the company’s development.

The Board is actively searching for a replacement non-executive Director.

With Dr Campbell resignation, the Board now consists of:

Chris Indermaur (Non-Executive Chairman)  
Kris Knauer (Executive Director)  
Dr Frank Prendergast (Non-Executive Director)

**Robert Lees**  
**Company Secretary**  
**Office:** +61 (02) 9299 9580  
**Fax:** +61 (0)2 9299 9501  
Email: [rob.lees@medibio.com.au](mailto:rob.lees@medibio.com.au)

### About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and Ottawa University, among others. The clinical trials will potentially enable Medibio’s technology to be the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental wellbeing which can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.